There’s reason to believe the stock can stage a comeback after its worst day in two decades.
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.
Danaher's rebound is generating optimism, but there's still work ahead for the company to hit is 2026 growth targets.
Danaher stock plunges despite Q2 earnings beat as the company cuts its 2026 core revenue growth forecast. Read details.
While the quarter was solid and 2026 is shaping up to be better than 2025, the progress has been slower than we would like.
The supplier of tools to drugmakers and hospitals is set up for a stronger 2026.
Danaher is finally turning the corner. CNBC's Jim Cramer sees it. Wall Street does, too.
Life sciences stocks are seeing a resurgence — and that's good news for Danaher.
